Dr. Rima Al-awar

PhD
Drug Discovery Program, Ontario Institute for Cancer Research (OICR)
Director and Senior Principal Investigator,, Senior Principal Investigator, Associate Graduate Faculty Member

Research Interests:

Optimize lead molecules, and progress them to drug candidates, that can translate into therapeutic benefits to cancer patients.

Brief Bio:

Dr. Al-awar is the Director and Senior Principal Investigator, Drug Discovery Program at the Ontario Institute for Cancer Research where she has been recruiting scientists and developing the Drug Discovery Program. The group is dedicated to the design, synthesis and evaluation of novel anti-tumour agents. The projects within the Drug Discovery Program focus largely on novel targets, with specific chemical probes being created to better understand cancer signalling pathways and potential points of therapeutic intervention. The major goal of the Drug Discovery group is to optimize lead molecules, and progress them to drug candidates, that can translate into therapeutic benefits to cancer patients.

Dr. Rima Al-awar

PhD
Drug Discovery Program, Ontario Institute for Cancer Research (OICR)
Director and Senior Principal Investigator,, Senior Principal Investigator, Associate Graduate Faculty Member

Research Interests:

Optimize lead molecules, and progress them to drug candidates, that can translate into therapeutic benefits to cancer patients.

Brief Bio:

Dr. Al-awar is the Director and Senior Principal Investigator, Drug Discovery Program at the Ontario Institute for Cancer Research where she has been recruiting scientists and developing the Drug Discovery Program. The group is dedicated to the design, synthesis and evaluation of novel anti-tumour agents. The projects within the Drug Discovery Program focus largely on novel targets, with specific chemical probes being created to better understand cancer signalling pathways and potential points of therapeutic intervention. The major goal of the Drug Discovery group is to optimize lead molecules, and progress them to drug candidates, that can translate into therapeutic benefits to cancer patients.